Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

The Word Brain 2015Free PDF | Print | Web
A short guide to fast language learning

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 205 articles:
HTML format
Text format



Single Articles


    May 2015
  1. THOMAS L
    Dermoscopy for melanoma: don't forget to take a photo.
    Br J Dermatol. 2015;172:1182-3.
    PubMed     Text format    


    April 2015
  2. JAFARI SM, Hunger RE, Shafighi M
    Lack of strong evidence in depth of thick melanoma excision.
    Br J Dermatol. 2015 Apr 27. doi: 10.1111/bjd.13871.
    PubMed     Text format     Abstract available


  3. PIZZICHETTA MA, Kittler H, Stanganelli I, Bono R, et al
    Pigmented nodular melanoma: The predictive value of dermoscopic features using a multivariate analysis.
    Br J Dermatol. 2015 Apr 27. doi: 10.1111/bjd.13861.
    PubMed     Text format     Abstract available


  4. SHITARAA D, Tell-Marti G, Badenas C, Enokihara MM, et al
    Mutational status of nevus associated-melanomas.
    Br J Dermatol. 2015 Apr 9. doi: 10.1111/bjd.13829.
    PubMed     Text format     Abstract available


  5. MARCHIORI BAKOS R
    Dermoscopy of naevoid melanoma.
    Br J Dermatol. 2015;172:848-9.
    PubMed     Text format    


  6. IDORN LW
    New insights into the association of socioeconomic status with cutaneous malignant melanoma.
    Br J Dermatol. 2015;172:846-7.
    PubMed     Text format    


    March 2015
  7. MAR VJ, Liu W, Devitt B, Wong SQ, et al
    The role of BRAF mutations in primary melanoma growth rate and survival.
    Br J Dermatol. 2015 Mar 5. doi: 10.1111/bjd.13756.
    PubMed     Text format     Abstract available


  8. FARIES MB, Cochran AJ, Elashoff RM, Thompson JF, et al
    Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: Response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal
    Br J Dermatol. 2015;172:571-3.
    PubMed     Text format     Abstract available


  9. SLADDEN M, Zagarella S, Popescu C, Bigby M, et al
    No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report.
    Br J Dermatol. 2015;172:566-71.
    PubMed     Text format     Abstract available


  10. ATTARD NR
    Head and neck melanoma: pattern of sun exposure and histological subtypes.
    Br J Dermatol. 2015;172:560-1.
    PubMed     Text format    


  11. SWETTER SM
    Thinner melanomas and improved survival among men in Sweden from 1997 to 2011.
    Br J Dermatol. 2015;172:559-60.
    PubMed     Text format    


  12. MCGREGOR JM, Sasieni P
    Sentinel node biopsy in cutaneous melanoma: time for consensus to better inform patient choice.
    Br J Dermatol. 2015;172:552-4.
    PubMed     Text format    


    February 2015
  13. CARRERA C
    High-risk melanoma patients: can unnecessary naevi biopsies be avoided?
    Br J Dermatol. 2015;172:313-5.
    PubMed     Text format    


    January 2015
  14. KASSIANOS AP, Emery JD, Murchie P, Walter FM, et al
    Smartphone applications for melanoma detection by community, patient and generalist clinician users: a review.
    Br J Dermatol. 2015 Jan 20. doi: 10.1111/bjd.13665.
    PubMed     Text format     Abstract available


    December 2014
  15. LIVINGSTONE E, Eigentler TK, Windemuth-Kieselbach C, Hauschild A, et al
    Actual practice of melanoma follow-up and treatment in Germany: Results of a prospective, longitudinal cohort study.
    Br J Dermatol. 2014 Dec 15. doi: 10.1111/bjd.13612.
    PubMed     Text format     Abstract available


  16. MORTON RL
    Essential inputs for studies of cost-effectiveness analysis in melanoma.
    Br J Dermatol. 2014;171:1294-5.
    PubMed     Text format    


  17. NALDI L
    Melanoma excision: how deep must we go?
    Br J Dermatol. 2014;171:1291-2.
    PubMed     Text format    


  18. BERMUDEZ Y
    Ultraviolet involvement in melanocyte transformation to melanoma.
    Br J Dermatol. 2014;171:1289.
    PubMed     Text format    


    November 2014
  19. GONZALEZ-ALVAREZ T, Carrera C, Bennassar A, Vilalta A, et al
    Dermoscopy structures predictors of sentinel lymph node positivity in cutaneous melanoma.
    Br J Dermatol. 2014 Nov 21. doi: 10.1111/bjd.13552.
    PubMed     Text format     Abstract available


  20. HUNGER RE, Seyed Jafari SM, Angermeier S, Shafighi M, et al
    Excision of fascia in melanoma thicker than 2 mm: no evidence for improved clinical outcome.
    Br J Dermatol. 2014 Nov 13. doi: 10.1111/bjd.13478.
    PubMed     Text format     Abstract available


  21. LONGO C, Piana S, Marghoob A, Cavicchini S, et al
    Morphologic features of nevoid melanoma Results of a Multicenter Study of the International Dermoscopy Society.
    Br J Dermatol. 2014 Nov 12. doi: 10.1111/bjd.13524.
    PubMed     Text format     Abstract available


  22. GARCIA-CASADO Z, Traves V, Banuls J, Niveiro M, et al
    BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
    Br J Dermatol. 2014 Nov 10. doi: 10.1111/bjd.13521.
    PubMed     Text format     Abstract available


  23. KITTLER H
    B-RAF, naevi and melanoma: a complex relationship.
    Br J Dermatol. 2014;171:931-932.
    PubMed     Text format    


    October 2014
  24. JIANG AJ, Rambhatla PV, Eide MJ
    A Systematic Review of Socioeconomic and Lifestyle Factors and Melanoma.
    Br J Dermatol. 2014 Oct 30. doi: 10.1111/bjd.13500.
    PubMed     Text format     Abstract available


  25. DABOUZ F, Barbe C, Lesage C, Le Clainche A, et al
    Clinical and histological features of head and neck melanoma: a population-based study in France.
    Br J Dermatol. 2014 Oct 21. doi: 10.1111/bjd.13489.
    PubMed     Text format     Abstract available


  26. MENIS D, Maronas-Jimenez L, Rodriguez-Peralto J, Martin-Llamas R, et al
    Two Spanish cases of Atypical Melanosis of the Foot, an early stage of Acral Lentiginous Melanoma in situ.
    Br J Dermatol. 2014 Oct 16. doi: 10.1111/bjd.13485.
    PubMed     Text format     Abstract available


  27. PONTI G, Manfredini M, Tomasi A, Pellacani G, et al
    Distinctive clinical and dermoscopic features of BRAFp.V600K mutated melanomas.
    Br J Dermatol. 2014 Oct 16. doi: 10.1111/bjd.13484.
    PubMed     Text format     Abstract available


  28. LYTH J, Eriksson H, Hansson J, Ingvar C, et al
    Trends in cutaneous malignant melanoma in Sweden 1997-2011: Thinner tumours and improved survival among men.
    Br J Dermatol. 2014 Oct 16. doi: 10.1111/bjd.13483.
    PubMed     Text format     Abstract available


  29. EVANS CL
    Peering under the skin: measuring melanoma depth with ultrasound and optical coherence tomography.
    Br J Dermatol. 2014;171:690-1.
    PubMed     Text format    


    September 2014
  30. WATTS CG, Dieng M, Morton RL, Mann GJ, et al
    Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review.
    Br J Dermatol. 2014 Sep 10. doi: 10.1111/bjd.13403.
    PubMed     Text format     Abstract available


    August 2014
  31. STANGANELLI I, Longo C, Mazzoni L, Magi S, et al
    Integration of reflectance confocal microscopy in sequential dermoscopy follow-up improves melanoma detection accuracy.
    Br J Dermatol. 2014 Aug 25. doi: 10.1111/bjd.13373.
    PubMed     Text format     Abstract available


  32. LAWRENCE CM, Rahim R, Charlton F, Husain A, et al
    Prospective study of formalin-fixed Mohs surgery and haematoxylin and eosin stains with control contralateral biopsies for lentigo maligna: 5-year follow-up results.
    Br J Dermatol. 2014;171:298-303.
    PubMed     Text format     Abstract available


    July 2014
  33. BERETTI F, Manni P, Longo C, Argenziano G, et al
    CD271 is expressed in melanoma with more aggressive behavior with correlation of characteristic morphology in in vivo reflectance confocal microscopy.
    Br J Dermatol. 2014 Jul 26. doi: 10.1111/bjd.13301.
    PubMed     Text format     Abstract available


  34. TROMME I, Devleesschauwer B, Beutels P, Richez P, et al
    Health related quality of life in melanoma patients expressed as utilities and disability weights.
    Br J Dermatol. 2014 Jul 12. doi: 10.1111/bjd.13262.
    PubMed     Text format     Abstract available


  35. ANFORTH R, Carlos G, Clements A, Kefford R, et al
    Cutaneous Adverse Events in Patients Treated with BRAF Inhibitor Based Therapies for Metastatic Melanoma for Longer than 52 Weeks.
    Br J Dermatol. 2014 Jul 9. doi: 10.1111/bjd.13200.
    PubMed     Text format     Abstract available


    June 2014
  36. SELLA T, Goren I, Shalev V, Shapira H, et al
    Incidence Trends of Keratinocytic Skin Cancers and Melanoma in Israel 2006-2011.
    Br J Dermatol. 2014 Jun 28. doi: 10.1111/bjd.13213.
    PubMed     Text format     Abstract available


  37. GAMBICHLER T, Kempka J, Kampilafkos P, Bechara FG, et al
    Clinicopathological characteristics of 270 lentigo maligna and lentigo maligna melanoma patients: data of a German Skin Cancer Center.
    Br J Dermatol. 2014 Jun 24. doi: 10.1111/bjd.13204.
    PubMed     Text format     Abstract available


  38. DE TROYA-MARTIN M, Rivas-Ruiz F, Blazquez-Sanchez N, Fernandez-Canedo I, et al
    Spanish version of the "skin cancer index". A questionnaire for measuring quality of life in patients with cervicofacial non-melanoma skin cancer.
    Br J Dermatol. 2014 Jun 7. doi: 10.1111/bjd.13173.
    PubMed     Text format     Abstract available


  39. ERIKSSON H, Frohm-Nilsson M, Jaras J, Kanter-Lewensohn L, et al
    Prognostic factors in localized invasive primary cutaneous malignant melanoma -results of a large population-based study.
    Br J Dermatol. 2014 Jun 7. doi: 10.1111/bjd.13171.
    PubMed     Text format     Abstract available


    May 2014
  40. MEYER N, Lauwers-Cances V, Lourari S, Laurent J, et al
    High frequency ultrasonography but not 930nm-optical coherence tomography reliably evaluates melanoma thickness in vivo: a prospective validation study.
    Br J Dermatol. 2014 May 23. doi: 10.1111/bjd.13129.
    PubMed     Text format     Abstract available


  41. MALVEHY J, Hauschild A, Curiel-Lewandrowski C, Mohr P, et al
    Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multi-centre, prospective and blinded clinical trial on efficacy and safety.
    Br J Dermatol. 2014 May 19. doi: 10.1111/bjd.13121.
    PubMed     Text format     Abstract available


  42. CHEVOLET I, Speeckaert R, Haspeslagh M, Neyns B, et al
    Peri-tumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
    Br J Dermatol. 2014 May 10. doi: 10.1111/bjd.13100.
    PubMed     Text format     Abstract available


    April 2014
  43. POZZOBON FC, Puig-Butille JA, Gonzalez-Alvarez T, Carrera C, et al
    Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
    Br J Dermatol. 2014 Apr 21. doi: 10.1111/bjd.13069.
    PubMed     Text format     Abstract available


  44. TALAGANIS JA, Biello K, Plaka M, Polydorou D, et al
    Demographic, behavioural and physician-related determinants of early melanoma detection in a low incidence population.
    Br J Dermatol. 2014 Apr 21. doi: 10.1111/bjd.13068.
    PubMed     Text format     Abstract available


  45. CHEVALIER V, Barbe C, Le Clainche A, Arnoult G, et al
    Comparison of Anatomic Locations of Cutaneous Melanoma in Men and Women: A Population-Based Study in France.
    Br J Dermatol. 2014 Apr 11. doi: 10.1111/bjd.13052.
    PubMed     Text format     Abstract available


  46. HOLLESTEIN LM, Nijsten T
    The association between beta-blockers and melanoma survival: evidence of absence or absence of evidence?
    Br J Dermatol. 2014;170:764-5.
    PubMed     Text format    


    March 2014
  47. ROTA M, Negri E, Pelucchi C, La Vecchia C, et al
    Does alcohol consumption increase risk of cutaneous melanoma? Comments on a recent meta-analysis: reply from authors.
    Br J Dermatol. 2014 Mar 26. doi: 10.1111/bjd.12996.
    PubMed     Text format     Abstract available


  48. SUN V, Zhou WB, Majid S, Kashani-Sabet M, et al
    MicroRNA-mediated regulation of melanoma.
    Br J Dermatol. 2014 Mar 26. doi: 10.1111/bjd.12989.
    PubMed     Text format     Abstract available


  49. PASTUSHENKO I, Vermeulen PB, Van den Eynden GG, Rutten A, et al
    Mechanisms of tumour vascularisation in cutaneous malignant melanoma: clinical implications.
    Br J Dermatol. 2014 Mar 18. doi: 10.1111/bjd.12973.
    PubMed     Text format     Abstract available


  50. CHEN GC, Zhang Y
    Does alcohol consumption increase risk of cutaneous melanoma? Comments on a recent meta-analysis.
    Br J Dermatol. 2014 Mar 18. doi: 10.1111/bjd.12971.
    PubMed     Text format     Abstract available


  51. PICARD M, Pham Dang N, D'Incan M, Mansard S, et al
    Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.
    Br J Dermatol. 2014 Mar 6. doi: 10.1111/bjd.12939.
    PubMed     Text format     Abstract available


  52. DE WAAL AC, van Harten-Gerritsen AS, Aben KK, Kiemeney LA, et al
    Impact of mitotic activity on the pathological sub-staging of pT1 cutaneous melanoma.
    Br J Dermatol. 2014 Mar 5. doi: 10.1111/bjd.12898.
    PubMed     Text format     Abstract available


  53. MCCOURT C, Coleman HG, Murray LJ, Cantwell MM, et al
    Beta-blocker usage after malignant melanoma diagnosis and survival: A population-based nested case-control study.
    Br J Dermatol. 2014 Mar 5. doi: 10.1111/bjd.12894.
    PubMed     Text format     Abstract available


  54. FORSEA AM, Del Marmol V, Stratigos A, Geller AC, et al
    Melanoma Prognosis in Europe: Far from Equal.
    Br J Dermatol. 2014 Mar 3. doi: 10.1111/bjd.12923.
    PubMed     Text format     Abstract available


    February 2014
  55. ROTA M, Pasquali E, Bellocco R, Bagnardi V, et al
    Alcohol drinking and cutaneous melanoma risk - A systematic review and dose-risk meta-analysis.
    Br J Dermatol. 2014 Feb 3. doi: 10.1111/bjd.12856.
    PubMed     Text format     Abstract available


  56. SACHSE MM, Wagner G
    Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids.
    Br J Dermatol. 2014;170:475-7.
    PubMed     Text format    


    January 2014
  57. CADBY G, Ward SV, Cole JM, Moses EK, et al
    The association of host and genetic melanoma risk factors with Breslow thickness in the Western Australian Melanoma Health Study.
    Br J Dermatol. 2014 Jan 9. doi: 10.1111/bjd.12829.
    PubMed     Text format     Abstract available


  58. CAPOLUONGO E, Paolillo C, Vendittelli F
    Is qRT-PCR MCAM transcript assay really suitable for prognostic and predictive management of melanoma patients?
    Br J Dermatol. 2014 Jan 7. doi: 10.1111/bjd.12818.
    PubMed     Text format     Abstract available


  59. JUNG GW, Dover DC, Salopek TG
    Risk of second primary malignancies following a diagnosis of cutaneous malignant melanoma or nonmelanoma skin cancer in Alberta, Canada from 1979 to 2009.
    Br J Dermatol. 2014;170:136-43.
    PubMed     Text format     Abstract available


  60. SULLIVAN RJ, Flaherty KT
    Major therapeutic developments and current challenges in advanced melanoma.
    Br J Dermatol. 2014;170:36-44.
    PubMed     Text format     Abstract available


  61. TSAO H
    Opening the melanoma black box.
    Br J Dermatol. 2014;170:9-10.
    PubMed     Text format    


  62. ECHEVERRIA B, Bulliard JL, Guillen C, Nagore E, et al
    Indicators for the total number of melanocytic naevi: an adjunct for screening campaigns. Observational study on 292 patients.
    Br J Dermatol. 2014;170:144-9.
    PubMed     Text format     Abstract available


  63. RIVERS JK
    Skin cancer: more than skin deep?
    Br J Dermatol. 2014;170:8.
    PubMed     Text format    


  64. FOGARTY GB, Hong A, Scolyer RA, Lin E, et al
    Radiotherapy for lentigo maligna: a literature review and recommendations for treatment.
    Br J Dermatol. 2014;170:52-8.
    PubMed     Text format     Abstract available


    December 2013
  65. DEBARBIEUX S, Perrot JL, Erfan N, Ronger-Savle S, et al
    Reflectance confocal microscopy of mucosal pigmented macules : a review of 56 cases including 10 macular melanoma.
    Br J Dermatol. 2013 Dec 20. doi: 10.1111/bjd.12803.
    PubMed     Text format     Abstract available


  66. ROSSI M, Tuck J, Kim OJ, Panova I, et al
    Neuropilin-2 Gene Expression Correlates with Malignant Progression in Cutaneous Melanoma.
    Br J Dermatol. 2013 Dec 20. doi: 10.1111/bjd.12801.
    PubMed     Text format     Abstract available


  67. IDORN LW, Wulf HC
    Socioeconomic status and cutaneous malignant melanoma in Northern Europe.
    Br J Dermatol. 2013 Dec 20. doi: 10.1111/bjd.12800.
    PubMed     Text format     Abstract available


  68. SINHA R, Lecamwasam K, Purshouse K, Reed J, et al
    Toxic Epidermal Necrolysis in a patient receiving Vemurafenib for treatment of metastatic malignant melanoma.
    Br J Dermatol. 2013 Dec 20. doi: 10.1111/bjd.12796.
    PubMed     Text format     Abstract available


  69. LOSI A, Longo C, Cesinaro AM, Benati E, et al
    Hyporeflective pagetoid cells: A new clue for amelanotic melanoma diagnosis by reflectance confocal microscopy.
    Br J Dermatol. 2013 Dec 14. doi: 10.1111/bjd.12781.
    PubMed     Text format     Abstract available


  70. KELLY JW, Shen S, Pan Y, Dowling J, et al
    Post-excisional melanocytic regrowth extending beyond the initial scar: A novel clinical sign of melanoma.
    Br J Dermatol. 2013 Dec 14. doi: 10.1111/bjd.12780.
    PubMed     Text format     Abstract available


  71. NARDONE B, Hammel JA, Raisch DW, Weaver LL, et al
    Melanoma Associated with TNFalpha Inhibitors: a Research on Adverse Drug events And Reports (RADAR) Project.
    Br J Dermatol. 2013 Dec 14. doi: 10.1111/bjd.12779.
    PubMed     Text format     Abstract available


    October 2013
  72. PASTUSHENKO I , Vermeulen PB, Carapeto FJ, Van den Eynden G, et al
    Blood Microvessel Density, Lymphatic Microvessel Density and Lymphatic Invasion in Predicting Melanoma Metastases: Systematic Review and Meta-Analysis.
    Br J Dermatol. 2013 Oct 17. doi: 10.1111/bjd.12688.
    PubMed     Text format     Abstract available


  73. FONG ZV , Tanabe KK
    Comparison of Melanoma Guidelines in the United States, Canada, Europe, Australia and New Zealand A critical appraisal and comprehensive review.
    Br J Dermatol. 2013 Oct 14. doi: 10.1111/bjd.12687.
    PubMed     Text format     Abstract available


  74. ALARCON I , Carrera C, Palou J, Alos L, et al
    Impact of in vivo reflectance confocal microscopy on the number needed to treat melanoma in doubtful lesions.
    Br J Dermatol. 2013 Oct 11. doi: 10.1111/bjd.12678.
    PubMed     Text format     Abstract available


  75. DOMINGUEZ-CRUZ JJ , Nieto-Garcia A, Rios JJ, Moreno-Ramirez D, et al
    Second non-melanoma skin cancer in Spain: frequency and chronology.
    Br J Dermatol. 2013 Oct 11. doi: 10.1111/bjd.12675.
    PubMed     Text format     Abstract available


    September 2013
  76. GERBER AL , Munst A, Schlapbach C, Shafighi M, et al
    High Expression Of Foxp3 In Primary Melanoma Is Associated With Tumour Progression.
    Br J Dermatol. 2013 Sep 30. doi: 10.1111/bjd.12641.
    PubMed     Text format     Abstract available


  77. KOOP A , Satzger I, Alter M, Kapp A, et al
    Intermittent B-Raf inhibitor therapy is a feasible option -report of a patient with metastatic melanoma.
    Br J Dermatol. 2013 Sep 6. doi: 10.1111/bjd.12615.
    PubMed     Text format     Abstract available


    August 2013
  78. RIBERO S , Osella-Abate S, Sanlorenzo M, Savoia P, et al
    Favourable Prognostic Role Of Regression Of Primary Melanoma In Stage I-Ii Ajcc Patients.
    Br J Dermatol. 2013 Aug 17. doi: 10.1111/bjd.12586.
    PubMed     Text format     Abstract available


  79. GRANGE F , Woronoff AS, Bera R, Colomb M, et al
    Efficacy of a general practitioner training campaign for early detection of melanoma in France.
    Br J Dermatol. 2013 Aug 12. doi: 10.1111/bjd.12585.
    PubMed     Text format     Abstract available


  80. FERRARI C , Seidenari S, Borsari S, Fabiano A, et al
    Dermoscopy of small melanomas: just a miniaturized dermoscopy?
    Br J Dermatol. 2013 Aug 2. doi: 10.1111/bjd.12542.
    PubMed     Text format     Abstract available


  81. REGNIER-ROSENCHER E , Lazareth H, Gressier L, Avril MF, et al
    Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.
    Br J Dermatol. 2013 Aug 2. doi: 10.1111/bjd.12555.
    PubMed     Text format     Abstract available


  82. MCGREGOR JM
    Too much surgery and too little benefit? Sentinel node biopsy for melanoma as it currently stands.
    Br J Dermatol. 2013;169:233-5.
    PubMed     Text format    


  83. DIFFEY B
    Sunbeds and young people: an easy target for legislation?
    Br J Dermatol. 2013;169:236-7.
    PubMed     Text format    


    July 2013
  84. LIU Z , Sun J, Smith M, Smith L, et al
    Incorporating Clinical Metadata with Digital Image Features for Automated Identification of Cutaneous Melanoma.
    Br J Dermatol. 2013 Jul 31. doi: 10.1111/bjd.12550.
    PubMed     Text format     Abstract available


  85. RAHIM RR , Husain A, Tobin DJ, Lawrence CM, et al
    Desmoplastic melanoma presenting with localised hair repigmentation.
    Br J Dermatol. 2013 Jul 20. doi: 10.1111/bjd.12521.
    PubMed     Text format     Abstract available


  86. ANFORTH R , Blumetti TC, Clements A, Kefford R, et al
    Systemic Retinoids for the Chemoprevention of Cutaneous Squamous Cell Carcinoma and Verrucal Keratosis in a Cohort of Patients on BRAF inhibitors.
    Br J Dermatol. 2013 Jul 20. doi: 10.1111/bjd.12519.
    PubMed     Text format     Abstract available


  87. GONZALEZ D , Fearfield L, Nathan P, Tanie're P, et al
    Concerns regarding BRAF testing in melanoma reply from authors.
    Br J Dermatol. 2013 Jul 16. doi: 10.1111/bjd.12509.
    PubMed     Text format     Abstract available


  88. EKEDAHL H , Cirenajwis H, Harbst K, Carneiro A, et al
    The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Br J Dermatol. 2013 Jul 16. doi: 10.1111/bjd.12504.
    PubMed     Text format     Abstract available


  89. LORIGAN P , Marples M, Harries M, Wagstaff J, et al
    Treatment patterns, outcomes, and resource utilisation of patients with metastatic melanoma in the U.K.: the MELODY study.
    Br J Dermatol. 2013 Jul 16. doi: 10.1111/bjd.12503.
    PubMed     Text format     Abstract available


  90. KASHANI-SABET M
    Molecular Markers in Melanoma.
    Br J Dermatol. 2013 Jul 1. doi: 10.1111/bjd.12493.
    PubMed     Text format     Abstract available


  91. NIKOLAOU V , Stratigos AJ
    Emerging trends in the epidemiology of melanoma.
    Br J Dermatol. 2013 Jul 1. doi: 10.1111/bjd.12492.
    PubMed     Text format     Abstract available


  92. ADAM A, Thomas L, Bories N, Zaharia D, et al
    Sarcoidosis associated with vemurafenib.
    Br J Dermatol. 2013;169:206-8.
    PubMed     Text format    


  93. SOYER HP , Prow TW
    Reflectance confocal microscopy in the diagnosis of nodular skin lesions.
    Br J Dermatol. 2013;169:4.
    PubMed     Text format    


  94. LONGO C, Farnetani F, Ciardo S, Cesinaro AM, et al
    Is confocal microscopy a valuable tool in diagnosing nodular lesions? A study of 140 cases.
    Br J Dermatol. 2013;169:58-67.
    PubMed     Text format     Abstract available


    June 2013
  95. WALLINGFORD SC , Alston RD, Birch JM, Green AC, et al
    Regional melanoma incidence in England, 1996-2006: reversal of north-south latitude trends among young females.
    Br J Dermatol. 2013 Jun 8. doi: 10.1111/bjd.12460.
    PubMed     Text format     Abstract available


  96. TITUS L
    Skin self-examination and the ABCDE rule in the early diagnosis of melanoma: is the game over? Reply from author.
    Br J Dermatol. 2013;168:1371-2.
    PubMed     Text format    


  97. DE GIORGI V , Papi F, Giorgi L, Savarese I, et al
    Skin self-examination and the ABCDE rule in the early diagnosis of melanoma: is the game over?
    Br J Dermatol. 2013;168:1370-1.
    PubMed     Text format    


  98. BLACK N
    Patient-reported outcome measures in skin cancer.
    Br J Dermatol. 2013;168:1151.
    PubMed     Text format    


  99. DE VRIES K, Rellum R, Habets JM, Prens EP, et al
    A novel two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod.
    Br J Dermatol. 2013;168:1362-4.
    PubMed     Text format    


    May 2013
  100. PICARD A , Tsilika K, Long-Mira E, Hofman P, et al
    Interest of High Definition Optical Coherent Tomography (HD-OCT) for imaging of melanoma.
    Br J Dermatol. 2013 May 11. doi: 10.1111/bjd.12433.
    PubMed     Text format     Abstract available


  101. GONZALEZ-HERRERO I , Romero-Camarero I, Canueto J, Cardenoso-Alvarez E, et al
    The CD133 cell content correlates with tumor growth in melanomas from skin with chronic sun-induced damage.
    Br J Dermatol. 2013 May 11. doi: 10.1111/bjd.12428.
    PubMed     Text format     Abstract available


  102. LADE-KELLER J , Riber-Hansen R, Guldberg P, Schmidt H, et al
    E- to N-cadherin switch in melanoma is associated with decreased expression of PTEN and cancer progression.
    Br J Dermatol. 2013 May 11. doi: 10.1111/bjd.12426.
    PubMed     Text format     Abstract available


  103. CAZENAVE H , Maubec E, Mohamdi H, Grange F, et al
    Anorectal and genital mucosal melanoma is associated with cutaneous melanoma in patients and in families.
    Br J Dermatol. 2013 May 6. doi: 10.1111/bjd.12421.
    PubMed     Text format     Abstract available


  104. PUIG-BUTILLE JA , Carrera C, Kumar R, Garcia-Casado Z, et al
    Distribution of MC1R variants among melanoma subtypes: p.R163Q is associated with Lentigo Maligna Melanoma in a Mediterranean population.
    Br J Dermatol. 2013 May 6. doi: 10.1111/bjd.12418.
    PubMed     Text format     Abstract available


  105. VAN DER LEEST RJ , Nijsten T, de Vries E
    Screening for second primary melanomas: is it efficient? Reply from authors.
    Br J Dermatol. 2013;168:1135.
    PubMed     Text format    


  106. GEURTS SM , van Dijck JA, Bonenkamp JJ, Soetekouw PM, et al
    Screening for second primary melanomas: is it efficient?
    Br J Dermatol. 2013;168:1133-5.
    PubMed     Text format    


  107. ROELANDTS R
    Determinants of personal ultraviolet radiation exposure doses on a sun holiday.
    Br J Dermatol. 2013;168:927.
    PubMed     Text format    


  108. PETERSEN B , Thieden E, Philipsen PA, Heydenreich J, et al
    Determinants of personal ultraviolet-radiation exposure doses on a sun holiday.
    Br J Dermatol. 2013;168:1073-9.
    PubMed     Text format     Abstract available


  109. HADJ-RABIA S , Oriot D, Soufir N, Dufresne H, et al
    Unexpected extradermatological findings in 31 patients with xeroderma pigmentosum type C.
    Br J Dermatol. 2013;168:1109-13.
    PubMed     Text format     Abstract available


    April 2013
  110. STANGANELLI I , Gandini S, Magi S, Mazzoni L, et al
    Sunbed use among subjects at high risk for melanoma: an Italian survey after the ban.
    Br J Dermatol. 2013 Apr 19. doi: 10.1111/bjd.12384.
    PubMed     Text format     Abstract available


  111. SCHLAAK M , Bajah A, Podewski T, Kreuzberg N, et al
    Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Br J Dermatol. 2013;168:708-16.
    PubMed     Text format     Abstract available


  112. WHITEMAN DC
    Prognostic sub-classifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark level of invasion. Results of a population-based study from the Swedish Melanoma Register.
    Br J Dermatol. 2013;168:685-6.
    PubMed     Text format    


  113. SAFAEE ARDEKANI G , Jafarnejad SM, Khosravi S, Martinka M, et al
    Disease Progression and Patient Survival Are Significantly Influenced by BRAF Protein Expression in Primary Melanoma.
    Br J Dermatol. 2013 Apr 1. doi: 10.1111/bjd.12351.
    PubMed     Text format     Abstract available


    March 2013
  114. HOLTERHUES C , Hollestein LM, Nijsten T, Koomen ER, et al
    Burden of disease due to cutaneous melanoma increased in the Netherlands since 1991.
    Br J Dermatol. 2013 Mar 29. doi: 10.1111/bjd.12346.
    PubMed     Text format     Abstract available


  115. GYLLENCREUTZ JD , Bostrom KB, Terstappen K
    Does it look like melanoma? A pilot study of the effect of sunless tanning on dermoscopy of pigmented skin lesions.
    Br J Dermatol. 2013 Mar 18. doi: 10.1111/bjd.12194.
    PubMed     Text format     Abstract available


  116. COSTA J , Ortiz-Ibanez K, Salerni G, Borges V, et al
    Dermoscopic patterns of Melanoma Metastases: inter-observer consistency and accuracy for metastases recognition.
    Br J Dermatol. 2013 Mar 18. doi: 10.1111/bjd.12314.
    PubMed     Text format     Abstract available


  117. GIBBONS E , Casanas I Comabella C, Fitzpatrick R
    A structured review of patient-reported outcome measures for patients with skin cancer, 2013.
    Br J Dermatol. 2013 Mar 14. doi: 10.1111/bjd.12310.
    PubMed     Text format     Abstract available


  118. TSIANAKAS A , Bohm MR, Getova V, Metze D, et al
    Skin metastases in metastatic uveal melanoma - GNAQ / GNA11 mutational analysis as a valuable tool.
    Br J Dermatol. 2013 Mar 6. doi: 10.1111/bjd.12291.
    PubMed     Text format     Abstract available


  119. GOLDSMITH SM
    Increased emphasis on darkness and rejection of a diameter criterion represent paradigm shifts in the clinical diagnosis of melanoma.
    Br J Dermatol. 2013 Mar 6. doi: 10.1111/bjd.12301.
    PubMed     Text format     Abstract available


  120. HUNTER HL , Dolan OM, McMullen E, Donnelly D, et al
    Incidence and survival in patients with cutaneous malignant melanoma: experience in a U.K. population, 1984-2009.
    Br J Dermatol. 2013;168:676-8.
    PubMed     Text format    


  121. MARPLES M
    Commentary: BRAF inhibitors for metastatic melanoma.
    Br J Dermatol. 2013;168:471-3.
    PubMed     Text format    


  122. HAUSCHILD A
    Response to a costly revolution for a subgroup of patients with metastatic melanoma.
    Br J Dermatol. 2013;168:470-1.
    PubMed     Text format    


  123. VAN AKKOOI AC , Nijsten T
    A costly revolution for a subgroup of patients with metastatic melanoma.
    Br J Dermatol. 2013;168:467-70.
    PubMed     Text format     Abstract available


    February 2013
  124. RAPANOTTI M , Ricozzi I, Campione E, Orlandi A, et al
    Blood MUC-18/MCAM expression in melanoma patients: a suitable marker of poor outcome.
    Br J Dermatol. 2013 Feb 28. doi: 10.1111/bjd.12295.
    PubMed     Text format     Abstract available


  125. LENORMAND C , Cribier B, Lipsker D
    Eruptive pigmentation around naevi and seborrhoeic keratoses in a patient with stage III melanoma: hyperpigmented halo or 'Nottus' phenomenon.
    Br J Dermatol. 2013 Feb 27. doi: 10.1111/bjd.12165.
    PubMed     Text format    


  126. TEULINGS HE , Tjin EP, Willemsen KJ, Krebbers G, et al
    Radiation induced melanoma-associated-leukoderma, systemic anti-melanoma immunity and disease-free survival in an advanced-stage melanoma patient: A case report and immunological analysis.
    Br J Dermatol. 2013 Feb 19. doi: 10.1111/bjd.12136.
    PubMed     Text format     Abstract available


  127. GREEN JS , Norris DA, Wisell J
    Novel Cutaneous Effects of Combination Chemotherapy with BRAF and MEK Inhibitors: a Report of Two Cases.
    Br J Dermatol. 2013 Feb 16. doi: 10.1111/bjd.12279.
    PubMed     Text format     Abstract available


  128. MOSCARELLA E , Rabinovitz H, Puig S, Zalaudek I, et al
    Multiple primary melanomas: do they look the same ?
    Br J Dermatol. 2013 Feb 3. doi: 10.1111/bjd.12260.
    PubMed     Text format     Abstract available


  129. OH BH , Lee SH, Nam KA, Lee HB, et al
    Comparison of negative pressure wound therapy and secondary intention healing after excision of acral lentiginous melanoma on the foot.
    Br J Dermatol. 2013;168:333-8.
    PubMed     Text format     Abstract available


    January 2013
  130. GONZALEZ D , Fearfield L, Nathan P, Taniere P, et al
    BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
    Br J Dermatol. 2013 Jan 29. doi: 10.1111/bjd.12248.
    PubMed     Text format     Abstract available


  131. DEBARBIEUX S , Dalle S, Depaepe L, Poulalhon N, et al
    Second primary melanomas under BRAF blockers: study by Reflectance Confocal Microscopy.
    Br J Dermatol. 2013 Jan 10. doi: 10.1111/bjd.12210.
    PubMed     Text format     Abstract available


  132. MUN JH , Kim GW, Jwa SW, Song M, et al
    Dermoscopy of subungual haemorrhage: Its usefulness in the differential diagnosis from nail unit melanoma.
    Br J Dermatol. 2013 Jan 10. doi: 10.1111/bjd.12209.
    PubMed     Text format     Abstract available


  133. PUPELLI G , Longo C, Veneziano L, Cesinaro AM, et al
    Small diameter melanocytic lesions: morphological analysis by means of in vivo confocal microscopy.
    Br J Dermatol. 2013 Jan 10. doi: 10.1111/bjd.12212.
    PubMed     Text format     Abstract available


  134. SULLIVAN R
    The challenge of developing useful blood-based biomarkers in melanoma.
    Br J Dermatol. 2013;168:3.
    PubMed     Text format    


    December 2012
  135. SAIAG P
    Toward a new place for dermatologists in the diagnosis of melanoma in France?
    Br J Dermatol. 2012;167:1199.
    PubMed     Text format    


    November 2012
  136. TEULINGS HE , Overkamp M, Ceylan E, Nieuweboer-Krobotova L, et al
    Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners.
    Br J Dermatol. 2012 Nov 9. doi: 10.1111/bjd.12111.
    PubMed     Text format     Abstract available


  137. MACKINTOSH LJ , Geddes CC, Herd RM
    Skin tumours in the West of Scotland renal transplant population.
    Br J Dermatol. 2012 Nov 8. doi: 10.1111/bjd.12129.
    PubMed     Text format     Abstract available


  138. BOCKLE BC , Stanarevic G, Ratzinger G, Sepp NT, et al
    Analysis of 303 Ro/SS-A antibody-positive patients: is this antibody a possible marker for malignancy?
    Br J Dermatol. 2012;167:1067-75.
    PubMed     Text format     Abstract available


    October 2012
  139. VAN DER VORST JR , Schaafsma BE, Verbeek FP, Swijnenburg RJ, et al
    Dose Optimization for Near-Infrared Fluorescence Sentinel Lymph Node Mapping in Melanoma Patients.
    Br J Dermatol. 2012 Oct 18. doi: 10.1111/bjd.12059.
    PubMed     Text format     Abstract available


  140. LYTH J , Hansson J, Ingvar C, Mansson-Brahme E, et al
    Prognostic sub-classifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion. Results of a population-based study from the Swedish Melanoma Register.
    Br J Dermatol. 2012 Oct 15. doi: 10.1111/bjd.12095.
    PubMed     Text format     Abstract available


  141. FEARFIELD L , Newton-Bishop JA, Sinha R, Edmonds K, et al
    Second perimary melanomas under vemurafenib - reply from the author.
    Br J Dermatol. 2012 Oct 15. doi: 10.1111/bjd.12094.
    PubMed     Text format     Abstract available


  142. DALLE S , Poulalhon N, Debarbieux S, Thomas L, et al
    Second primary melanomas under vemurafenib.
    Br J Dermatol. 2012 Oct 15. doi: 10.1111/bjd.12093.
    PubMed     Text format     Abstract available


    September 2012
  143. GRANT WB
    Disparities in melanoma incidence rates in Europe.
    Br J Dermatol. 2012 Sep 26. doi: 10.1111/bjd.12054.
    PubMed     Text format     Abstract available


  144. IDORN LW , Datta P, Heydenreich J, Philipsen PA, et al
    Sun behaviour after cutaneous malignant melanoma A study based on ultraviolet radiation measurements and sun diary data.
    Br J Dermatol. 2012 Sep 26. doi: 10.1111/bjd.12066.
    PubMed     Text format     Abstract available


  145. REID AL , Millward M, Pearce R, Lee M, et al
    Markers of circulating tumour cells in the peripheral blood of melanoma patients correlates with disease recurrence and progression.
    Br J Dermatol. 2012 Sep 26. doi: 10.1111/bjd.12057.
    PubMed     Text format     Abstract available


  146. DE GIORGI V , Gori A, Gandini S, Papi F, et al
    Estrogen receptor beta and melanoma. A comparative study.
    Br J Dermatol. 2012 Sep 26. doi: 10.1111/bjd.12056.
    PubMed     Text format     Abstract available


    August 2012
  147. SINHA R , Edmonds K, Newton-Bishop JA, Gore ME, et al
    Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.
    Br J Dermatol. 2012 Aug 22. doi: 10.1111/bjd.12010.
    PubMed     Text format     Abstract available


  148. TITUS LJ , Clough-Gorr K, Mackenzie TA, Perry A, et al
    Recent Skin Self-Examination and Doctor Visits in Relation to Melanoma Risk and Tumor Depth.
    Br J Dermatol. 2012 Aug 16. doi: 10.1111/bjd.12003.
    PubMed     Text format     Abstract available


  149. GAMBICHLER T , Bindsteiner M, Hoxtermann S, Kreuter A, et al
    Serum 25-hydroxyvitamin D serum levels in a large German cohort of melanoma patients.
    Br J Dermatol. 2012 Aug 9. doi: 10.1111/j.1365-2133.2012.11212.
    PubMed     Text format     Abstract available


  150. STRATIGOS AJ , Forsea AM, van der Leest RJ, de Vries E, et al
    Euromelanoma: a dermatology-led European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future.
    Br J Dermatol. 2012;167 Suppl 2:99-104.
    PubMed     Text format     Abstract available


  151. DE VRIES E , Arnold M, Altsitsiadis E, Trakatelli M, et al
    Potential impact of interventions resulting in reduced exposure to ultraviolet (UV) radiation (UVA and UVB) on skin cancer incidence in four European countries, 2010-2050.
    Br J Dermatol. 2012;167 Suppl 2:53-62.
    PubMed     Text format     Abstract available


  152. DE VRIES E , Trakatelli M, Kalabalikis D, Ferrandiz L, et al
    Known and potential new risk factors for skin cancer in European populations: a multicentre case-control study.
    Br J Dermatol. 2012;167 Suppl 2:1-13.
    PubMed     Text format     Abstract available


    July 2012
  153. GRANGE F , Barbe C, Mas L, Granel-Brocard F, et al
    The role of general practitioners in diagnosis of cutaneous melanoma: a population-based study in France.
    Br J Dermatol. 2012 Jul 27. doi: 10.1111/j.1365-2133.2012.11178.
    PubMed     Text format     Abstract available


  154. ANFORTH RM , Blumetti TC, Kefford RF, Sharma R, et al
    Cutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in patients with Metastatic Melanoma.
    Br J Dermatol. 2012 Jul 16. doi: 10.1111/j.1365-2133.2012.11155.
    PubMed     Text format     Abstract available


  155. RICHTIG E , Schrama D, Ugurel S, Fried I, et al
    BRAF mutation analysis of only one single metastatic lesion can restrict the treatment of melanoma - a case report.
    Br J Dermatol. 2012 Jul 7. doi: 10.1111/j.1365-2133.2012.11121.
    PubMed     Text format     Abstract available


  156. ROBSON Y , Blackford S, Roberts D
    Caution in melanoma risk analysis with smartphone application technology.
    Br J Dermatol. 2012 Jul 5. doi: 10.1111/j.1365-2133.2012.11046.
    PubMed     Text format    


  157. LUTTRELL MJ , McClenahan P, Hofmann-Wellenhof R, Fink-Puches R, et al
    Laypersons' sensitivity for melanoma identification is higher with dermoscopy images than clinical photographs.
    Br J Dermatol. 2012 Jul 4. doi: 10.1111/j.1365-2133.2012.11130.
    PubMed     Text format     Abstract available


  158. FORSEA AM , Del Marmol V, de Vries E, Bailey EE, et al
    Melanoma incidence and mortality in Europe: new estimates, persistent disparities.
    Br J Dermatol. 2012 Jul 3. doi: 10.1111/j.1365-2133.2012.11125.
    PubMed     Text format     Abstract available


  159. VAN DER LEEST RJ , Liu L, Coebergh JW, Neumann HA, et al
    Risk of second primary in situ and invasive melanoma in Dutch population-based cohort: 1989 - 2008.
    Br J Dermatol. 2012 Jul 3. doi: 10.1111/j.1365-2133.2012.11123.
    PubMed     Text format     Abstract available


    June 2012
  160. JUNG GW , Weinstock MA
    Clinicopathologic comparisons of index and second primary melanomas in pediatric and adult populations.
    Br J Dermatol. 2012 Jun 20. doi: 10.1111/j.1365-2133.2012.11097.
    PubMed     Text format     Abstract available


  161. DEBARBIEUX S , Hospod V, Depaepe L, Balme B, et al
    Peroperative confocal microscopy of the nail matrix in the management of in situ or minimally invasive subungual melanomas.
    Br J Dermatol. 2012 Jun 7. doi: 10.1111/j.1365-2133.2012.11013.
    PubMed     Text format     Abstract available


  162. STURM RA
    GSTP1 and MC1R in melanoma susceptibility.
    Br J Dermatol. 2012;166:1155-6.
    PubMed     Text format    


    May 2012
  163. YOUL PH , Youlden DR, Baade PD
    Changes in the site distribution of common melanoma sub-types in Queensland, Australia over time: implications for public health campaigns.
    Br J Dermatol. 2012 May 21. doi: 10.1111/j.1365-2133.2012.11064.
    PubMed     Text format     Abstract available


  164. MILLINGTON GW
    Leptin, obesity and cutaneous melanoma.
    Br J Dermatol. 2012 May 14. doi: 10.1111/j.1365-2133.2012.10757.
    PubMed     Text format    


  165. TROMME I , Sacre L, Hammouch F, Legrand C, et al
    Availability of digital dermoscopy in daily practice dramatically reduces the number of excised melanocytic lesions: results from an observational study.
    Br J Dermatol. 2012 May 7. doi: 10.1111/j.1365-2133.2012.11042.
    PubMed     Text format     Abstract available


  166. EISEMANN N , Jansen L, Holleczek B, Waldmann A, et al
    Up-to-date survival of melanoma patients in Germany.
    Br J Dermatol. 2012 May 5. doi: 10.1111/j.1365-2133.2012.11039.
    PubMed     Text format     Abstract available


    April 2012
  167. NAGEL G , Bjorge T, Stocks T, Manjer J, et al
    Metabolic risk factors and skin cancer in the Metabolic Syndrome and Cancer Project (Me-Can).
    Br J Dermatol. 2012 Apr 24. doi: 10.1111/j.1365-2133.2012.10974.
    PubMed     Text format     Abstract available


  168. LOVE PB , Nelson KC
    Melanoma of the hand and foot: a distinct clinical variant of cutaneous melanoma.
    Br J Dermatol. 2012;166:708.
    PubMed     Text format    


    March 2012
  169. MOSCARELLA E , Zalaudek I, Cerroni L, Sperduti I, et al
    Excised melanocytic lesions in children and adolescents: A ten-year survey.
    Br J Dermatol. 2012 Mar 19. doi: 10.1111/j.1365-2133.2012.10952.
    PubMed     Text format     Abstract available


  170. PRALONG P , Bathelier E, Dalle S, Poulalhon N, et al
    Dermoscopy of Lentigo Maligna Melanoma: Report of 125 Cases.
    Br J Dermatol. 2012 Mar 8. doi: 10.1111/j.1365-2133.2012.10932.
    PubMed     Text format     Abstract available


    February 2012
  171. HAO L , Ha JR, Kuzel P, Garcia E, et al
    Cadherin Switch from E- to N-Cadherin in Melanoma Progression is regulated by the PI3K/PTEN Pathway through TWIST and SNAIL.
    Br J Dermatol. 2012 Feb 14. doi: 10.1111/j.1365-2133.2012.10824.
    PubMed     Text format     Abstract available


    January 2012
  172. TAKEI Y , Huynh KT, Kuo C, Scolyer RA, et al
    Aberrant Hypermethylation in Primary and Sentinel Lymph Node Metastases in Pediatric Cutaneous Melanoma Patients.
    Br J Dermatol. 2012 Jan 31. doi: 10.1111/j.1365-2133.2012.10867.
    PubMed     Text format     Abstract available


  173. BALOGH K , Szell M, Polyanka H, Pagani F, et al
    Detection of a rare CDKN2A intronic mutation in a Hungarian melanoma-prone family and its role in splicing regulation.
    Br J Dermatol. 2012 Jan 31. doi: 10.1111/j.1365-2133.2012.10864.
    PubMed     Text format     Abstract available


  174. TERUSHKIN V , Dusza SW, Scope A, Argenziano G, et al
    Changes observed in slow growing melanomas during long-term dermoscopic monitoring.
    Br J Dermatol. 2012 Jan 27. doi: 10.1111/j.1365-2133.2012.10846.
    PubMed     Text format     Abstract available


  175. IBARROLA-VILLAVA M , Martin-Gonzalez M, Lazaro P, Pizarro A, et al
    Role of GSTs in Melanoma Susceptibility: Association with rs1695 GSTP1 Polymorphism.
    Br J Dermatol. 2012 Jan 17. doi: 10.1111/j.1365-2133.2012.10831.
    PubMed     Text format     Abstract available


  176. LOMAS A , Leonardi-Bee J, Bath-Hextall F
    A Systematic Review of worldwide incidence of Non-melanoma skin cancer.
    Br J Dermatol. 2012 Jan 17. doi: 10.1111/j.1365-2133.2012.10830.
    PubMed     Text format     Abstract available


    December 2011
  177. DURBEC F , Martin L, Derancourt C, Grange F, et al
    Melanoma of the hand and foot Epidemiologic, prognostic and genetic features: a systematic review.
    Br J Dermatol. 2011 Dec 17. doi: 10.1111/j.1365-2133.2011.10772.
    PubMed     Text format    


  178. LEE HJ , Park MK, Kim SY, Park Choo HY, et al
    Serotonin induces melanogenesis via serotonin receptor 2A.
    Br J Dermatol. 2011;165:1344-8.
    PubMed     Text format     Abstract available


    November 2011
  179. MILLINGTON GW
    Leptin, Obesity and Cutaneous Melanoma.
    Br J Dermatol. 2011 Nov 28. doi: 10.1111/j.1365-2133.2011.10757.
    PubMed     Text format    


  180. DE GIORGI V , Gori A, Grazzini M, Rossari S, et al
    Obesity and Melanoma.
    Br J Dermatol. 2011 Nov 19. doi: 10.1111/j.1365-2133.2011.10752.
    PubMed     Text format    


    October 2011
  181. LEVELL NJ
    English melanoma by body site: keep wearing the trousers?
    Br J Dermatol. 2011;165:709-10.
    PubMed     Text format    


    September 2011
  182. POLOM K , Murawa D, Rho SY, Spychala A, et al
    Skin Melanoma Sentinel Lymph Node Biopsy Using Real Time Fluorescence Navigation With Indocyanine Green and Indocyanine Green With Human Serum Albumin.
    Br J Dermatol. 2011 Sep 16. doi: 10.1111/j.1365-2133.2011.10634.
    PubMed     Text format    


  183. GILES N , Pavey S, Pinder A, Gabrielli B, et al
    Multiple melanoma susceptibility factors function in a UVR response pathway in skin.
    Br J Dermatol. 2011 Sep 16. doi: 10.1111/j.1365-2133.2011.10635.
    PubMed     Text format     Abstract available


  184. YUN SJ , Kwon OS, Han JH, Kweon SS, et al
    Clinical Characteristics and Risk of Melanoma Development from Giant Congenital Melanocytic Naevi in Korea: A Nationwide Retrospective Study.
    Br J Dermatol. 2011 Sep 16. doi: 10.1111/j.1365-2133.2011.10636.
    PubMed     Text format     Abstract available


  185. ARGENZIANO G , Longo C, Cameron A, Cavicchini S, et al
    Blue-black rule: a simple dermoscopic clue to recognize pigmented nodular melanoma.
    Br J Dermatol. 2011 Sep 14. doi: 10.1111/j.1365-2133.2011.10621.
    PubMed     Text format     Abstract available


    August 2011
  186. SUREDA N , Phan A, Poulalhon N, Balme B, et al
    Conservative surgical management of subungual (matrix derived) melanoma: report of seven cases and literature review.
    Br J Dermatol. 2011 Aug 4. doi: 10.1111/j.1365-2133.2011.10477.
    PubMed     Text format     Abstract available


  187. NIKOLAOU V , Kang X, Stratigos A, Gogas H, et al
    Comprehensive mutational analysis of CDKN2A and CDK4 in greek patients with cutaneous melanoma.
    Br J Dermatol. 2011 Aug 1. doi: 10.1111/j.1365-2133.2011.10551.
    PubMed     Text format     Abstract available


  188. LODEN M , Beitner H, Gonzalez H, Edstrom DW, et al
    Sunscreen use: controversies, challenges and regulatory aspects.
    Br J Dermatol. 2011;165:255-62.
    PubMed     Text format     Abstract available


    July 2011
  189. SUPPA M , Elliott F, Mikeljevic JS, Mukasa Y, et al
    The determinants of periorbital skin aging in participants of a melanoma case control study in the UK.
    Br J Dermatol. 2011 Jul 23. doi: 10.1111/j.1365-2133.2011.10536.
    PubMed     Text format     Abstract available


  190. DIFFEY BL
    In praise of small studies.
    Br J Dermatol. 2011;165:3-4.
    PubMed     Text format    


    June 2011
  191. FEITO-RODRIGUEZ M , de Lucas-Laguna R, Bastian BC, Leboit P, et al
    Nodular lesions arising in a large congenital melanocytic nevus in a newborn with eruptive disseminated spitz nevi (nodular lesions arising in a congenital melanocytic nevus and eruptive spitz nevi).
    Br J Dermatol. 2011 Jun 28. doi: 10.1111/j.1365-2133.2011.10502.
    PubMed     Text format     Abstract available


    May 2011
  192. WALLINGFORD SC , Alston RD, Birch JM, Green AC, et al
    Increases in invasive melanoma in England, 1979-2006, by anatomic site.
    Br J Dermatol. 2011 May 28. doi: 10.1111/j.1365-2133.2011.10434.
    PubMed     Text format     Abstract available


  193. DIAZ-CANO SJ
    Paratumoral gene expression profiles: Promising markers of malignancy in melanocytic lesions.
    Br J Dermatol. 2011 May 28. doi: 10.1111/j.1365-2133.2011.10437.
    PubMed     Text format     Abstract available


  194. OBA J , Moroi Y, Nakahara T, Abe T, et al
    Title: Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma.
    Br J Dermatol. 2011 May 17. doi: 10.1111/j.1365-2133.2011.10409.
    PubMed     Text format     Abstract available


  195. PARADISI A , Waterboer T, Sampogna F, Tabolli S, et al
    SEROPOSITIVITY FOR HUMAN PAPILLOMAVIRUS AND INCIDENCE OF SUBSEQUENT SQUAMOUS CELL AND BASAL CELL CARCINOMAS OF THE SKIN IN PATIENTS WITH A PREVIOUS NON-MELANOMA SKIN CANCER.
    Br J Dermatol. 2011 May 11. doi: 10.1111/j.1365-2133.2011.10403.
    PubMed     Text format     Abstract available


    April 2011
  196. SCHOENEWOLF NL , Urosevic-Maiwald M, Dummer R
    Tumor heterogeneity of mucosal melanomas during treatment with imatinib.
    Br J Dermatol. 2011 Apr 18. doi: 10.1111/j.1365-2133.2011.10376.
    PubMed     Text format     Abstract available


  197. FUGLEDE NB , Brinck-Claussen UO, Deltour I, Boesen EH, et al
    Incidence of cutaneous malignant melanoma in Denmark, 1978-2007.
    Br J Dermatol. 2011 Apr 5. doi: 10.1111/j.1365-2133.2011.10361.
    PubMed     Text format     Abstract available


  198. TENNIS P , Gelfand JM, Rothman KJ
    Evaluation of Cancer Risk Related to Atopic Dermatitis and Use of Topical Calcineurin Inhibitors.
    Br J Dermatol. 2011 Apr 5. doi: 10.1111/j.1365-2133.2011.10363.
    PubMed     Text format     Abstract available


  199. BRANDT A , Sundquist J, Hemminki K
    Risk of incident and fatal melanoma in individuals with a family history of incident or fatal melanoma or any cancer.
    Br J Dermatol. 2011 Apr 1. doi: 10.1111/j.1365-2133.2011.10350.
    PubMed     Text format     Abstract available


  200. IDORN LW , Philipsen PA, Wulf HC
    Sun exposure before and after a diagnosis of cutaneous malignant melanoma: estimated by developments in serum vitamin D, skin pigmentation and interviews.
    Br J Dermatol. 2011 Apr 1. doi: 10.1111/j.1365-2133.2011.10348.
    PubMed     Text format     Abstract available


  201. GRICHNIK JM
    Stratum corneum RNA levels are diagnostic for melanoma.
    Br J Dermatol. 2011;164:693-4.
    PubMed     Text format    


  202. ARGENZIANO G , Catricala C, Ardigo M, Buccini P, et al
    Seven-point checklist of dermoscopy revisited.
    Br J Dermatol. 2011;164:785-90.
    PubMed     Text format     Abstract available


    February 2011
  203. PAUROBALLY D , Jason F, Dezfoulian B, Nikkels AF, et al
    Melanotan-associated melanoma.
    Br J Dermatol. 2011 Feb 24. doi: 10.1111/j.1365-2133.2011.10273.
    PubMed     Text format    


    January 2011
  204. TJIU JW , Lin PJ, Wu WH, Cheng YP, et al
    SLURP1 mutation-impaired T-cell activation in a family with mal de Meleda.
    Br J Dermatol. 2011;164:47-53.
    PubMed     Text format    


    December 2010
  205. AKAY BN , Kocyigit P, Heper AO, Erdem C, et al
    Dermatoscopy of flat pigmented facial lesions: diagnostic challenge between pigmented actinic keratosis and lentigo maligna.
    Br J Dermatol. 2010;163:1212-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


All AMEDEO services are free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Amedeo is a Flying Publisher website.

   Design: